

CITATION REPORT

List of articles citing

Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells

DOI: 10.1007/s002620050016

Cancer Immunology, Immunotherapy, 2000, 48, 673-83.

Source: <https://exaly.com/paper-pdf/31597513/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
361	Anti-CD30 antibody-based therapy. 2000 , 12, 588-93		21
360	In vitro and in vivo purging of B lymphoma cells from stem-cell products using anti-CD20 Abs. 2000 , 2, 445-53		2
359	Epstein-Barr virus in patients with immunodeficiency disorders. 2001 , 55, 353-61		12
358	Human therapeutic antibodies. 2001 , 1, 404-8		22
357	Current concepts in cancer vaccine strategies. 2001 , 30, 170-2, 174, 176 passim		22
356	Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma. <i>Blood</i> , 2001 , 98, 1352-7	2.2	189
355	Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species. <i>Blood</i> , 2001 , 98, 2771-7	2.2	175
354	Immunotherapy of Non-Hodgkin's lymphomas. <i>Hematology American Society of Hematology Education Program</i> , 2001 , 2001, 221-40	3.1	64
353	Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. 2001 , 114, 800-9		159
352	Rituximab: perspective on single agent experience, and future directions in combination trials. 2001 , 40, 3-16		61
351	Characterization of BIS20x3, a bi-specific antibody activating and retargeting T-cells to CD20-positive B-cells. 2001 , 84, 1115-21		5
350	CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells. 2001 , 15, 1619-26		120
349	Src protein tyrosine kinases in stress responses. 2002 , 6, 1-12		0
348	Rituximab: clinical development and future directions. 2002 , 2, 97-110		29
347	[Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -- results of a prospective randomized study of the German Low-Grade Lymphoma Study Group]. 2002 , 127, 2253-8		7
346	Analysis of CD20-dependent cellular cytotoxicity by G-CSF-stimulated neutrophils. 2002 , 16, 693-9		52
345	Application of recombinant antibodies in cancer patients. <i>Methods in Molecular Biology</i> , 2003 , 207, 27-53		4

344	The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. <i>Blood</i> , 2002 , 99, 1038-43	2.2	324
343	Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure. <i>Blood</i> , 2002 , 99, 3256-62	2.2	133
342	Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. <i>Blood</i> , 2002 , 99, 754-8	2.2	1607
341	Future of monoclonal antibodies in the treatment of hematologic malignancies. 2002 , 9, 152-66		64
340	Treatment of Waldenström's macroglobulinemia with rituximab. 2002 , 20, 2327-33		212
339	Antibody-based therapy of non-Hodgkin's lymphoma. 2002 , 15, 449-65		6
338	Mantle cell lymphoma: new treatments targeted to the biology. 2002 , 3, 90-6		5
337	Extended rituximab therapy for previously untreated patients with Waldenström's macroglobulinemia. 2002 , 3, 163-6		60
336	Recombinant Antibodies for Cancer Therapy. 2002 ,		
335	Rituximab and rapamycin for posttransplant lymphoproliferative disease treatment: report of three cases. 2002 , 34, 2993-5		18
334	The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism. <i>Blood</i> , 2002 , 99, 1314-9	2.2	187
333	Rituximab in the treatment of diffuse large B-cell lymphomas. 2002 , 29, 30-35		42
332	Rituximab: Mechanism of action and resistance. 2002 , 29, 2-9		236
331	Increasing treatment options in indolent non-Hodgkin's lymphoma. 2002 , 29, 2-6		6
330	Improving outcomes in transplantation. 2002 , 29, 23-6		7
329	Combination of chemotherapy and monoclonal antibodies for the treatment of lymphoma. 2002 , 76, 394-400		6
328	CD20-mediated apoptosis: signalling through lipid rafts. 2002 , 107, 176-82		197
327	Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. 2002 , 117, 828-34		116

326	Down regulation of B cells by immunization with a fusion protein of a self CD20 peptide and a foreign IgG.Fc fragment. 2002 , 81, 49-58	7
325	CD20-induced B cell death can bypass mitochondria and caspase activation. 2002 , 16, 1735-44	74
324	Cross-priming of cytotoxic T cells promoted by apoptosis-inducing tumor cell reactive antibodies?. 2002 , 22, 124-30	59
323	Inhibitory effects of extracellular Mg ²⁺ on intracellular Ca ²⁺ dynamic changes and thapsigargin-induced apoptosis in human cancer MCF7 cells. 2002 , 229, 163-71	17
322	Recombinant antibodies for the diagnosis and treatment of cancer. 2003 , 25, 1-17	11
321	Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. 2003 , 21, 3940-7	1112
320	Antibody therapy of non-Hodgkin's B-cell lymphoma. <i>Cancer Immunology, Immunotherapy</i> , 2003 , 52, 257-80	39
319	Immunotherapy with anti-CD20 compounds. 2003 , 13, 211-22	14
318	The mechanisms of action of rituximab in the elimination of tumor cells. 2003 , 30, 3-8	166
317	Radioimmunotherapy for Waldenstrom's macroglobulinemia. 2003 , 30, 258-61	8
316	Mechanism of action and resistance to monoclonal antibody therapy. 2003 , 30, 424-33	71
315	The relationship of Fcγ ₃ genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. 2003 , 48, 455-9	375
314	Lymphocyte subsets may discern treatment effects in children and young adults with post-transplant lymphoproliferative disorder. 2003 , 7, 370-5	7
313	Costimulatory signals distinctively affect CD20- and B-cell-antigen-receptor-mediated apoptosis in Burkitt's lymphoma/leukemia cells. 2003 , 17, 1164-74	13
312	Mitochondria control of cell death induced by anti-HLA-DR antibodies. 2003 , 17, 1357-65	27
311	A cholesterol-dependent CD20 epitope detected by the FMC7 antibody. 2003 , 17, 1384-9	23
310	Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: final report on safety and efficacy. 2003 , 17, 1658-64	52
309	Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. 2003 , 22, 7359-68	578

308	Monoclonal antibody therapeutics and apoptosis. 2003 , 22, 9097-106		58
307	Monoclonal antibodies combined to chemotherapy for the treatment of patients with lymphoma. <i>Blood Reviews</i> , 2003 , 17, 25-31	11.1	22
306	Rituximab in association with rapamycin for post-transplant lymphoproliferative disease treatment. 2003 , 16, 202-206		45
305	Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. 2003 , 63, 803-43		341
304	Rafts: a simple way to control apoptosis by subcellular redistribution. 2003 , 85, 727-31		39
303	Lymphoma updates. 2003 , 33, 455-71		19
302	Monoclonal antibody therapy for cancer. 2003 , 54, 343-69		158
301	Spotlight on Rituximab in Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia. 2003 , 2, 283-289		
300	Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). <i>Blood</i> , 2003 , 101, 4279-84	2.2	428
299	Adding cytokines to monoclonal antibody therapy: does the concurrent administration of interleukin-12 add to the efficacy of rituximab in B-cell non-hodgkin lymphoma?. 2003 , 44, 1309-15		13
298	Variation in gene expression patterns in follicular lymphoma and the response to rituximab. 2003 , 100, 1926-30		128
297	Monoclonal antibody therapy of chronic lymphocytic leukemia. 2003 , 21, 1874-81		59
296	Role of RLIP76 in lung cancer doxorubicin resistance: III. Anti-RLIP76 antibodies trigger apoptosis in lung cancer cells and synergistically increase doxorubicin cytotoxicity. 2003 , 22, 721		4
295	In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. <i>Blood</i> , 2003 , 101, 949-54.	2	294
294	An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab. <i>Blood</i> , 2003 , 101, 1071-9	2.2	132
293	Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. <i>Blood</i> , 2003 , 101, 1045-52	2.2	303
292	Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia. <i>Blood</i> , 2003 , 102, 3514-20	2.2	107
291	The role of therapeutic antibodies in drug discovery. 2003 , 31, 433-6		37

290	Antibody therapy of lymphoma. 2004 , 51, 229-53	5
289	Molecular biological design of novel antineoplastic therapies. 2004 , 13, 577-607	4
288	Monoclonal antibody therapy of B cell lymphoma. 2004 , 4, 375-85	16
287	Iodine-131 tositumomab (Bexxar): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin's lymphoma. 2004 , 4, 18-26	22
286	Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab. <i>Cancer Research</i> , 2004 , 64, 7117-26 ^{10.1}	174
285	Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. <i>Cancer Research</i> , 2004 , 64, 4664-9	10.1 356
284	The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. 2004 , 199, 1659-69	521
283	The role of B cell-mediated T cell costimulation in the efficacy of the T cell retargeting bispecific antibody BIS20x3. 2004 , 173, 6009-16	2
282	Empowering targeted therapy: lessons from rituximab. 2004 , 2004, pe30	19
281	Rituximab: expanding role in therapy for lymphomas and autoimmune diseases. 2004 , 55, 477-503	181
280	The biology of CD20 and its potential as a target for mAb therapy. 2005 , 8, 140-74	248
279	The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. 2004 , 125, 232-9	238
278	Apoptotic effect of rituximab on peripheral blood B cells in rheumatoid arthritis. 2004 , 60, 209-18	35
277	Inhibition of survivin expression suppresses the growth of aggressive non-Hodgkin's lymphoma. 2004 , 18, 616-23	79
276	Apoptosis induced by molecular targeting therapy in hematological malignancies. 2004 , 111, 107-23	15
275	Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells. 2004 , 83, 634-45	91
274	Radiobiology of radioimmunotherapy: targeting CD20 B-cell antigen in non-Hodgkin's lymphoma. 2004 , 59, 1274-87	60
273	Monoclonal antibodies in the treatment of chronic lymphoid leukemias. 2004 , 45, 205-19	45

272	From the bench to the bedside: ways to improve rituximab efficacy. <i>Blood</i> , 2004 , 104, 2635-42	2.2	443
271	Inhibition of human B-cell lymphoma by an anti-CD20 antibody and its chimeric F(ab') ₂ fragment via induction of apoptosis. 2004 , 205, 143-53		4
270	2D7 diabody bound to the alpha2 domain of HLA class I efficiently induces caspase-independent cell death against malignant and activated lymphoid cells. 2004 , 325, 1201-9		9
269	Non-Hodgkin lymphoma: an update. 2004 , 5, 341-53		154
268	Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody). 2004 , 140, 91-6		96
267	Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. <i>Blood</i> , 2004 , 103, 2738-43		282
266	Fenretinide enhances rituximab-induced cytotoxicity against B-cell lymphoma xenografts through a caspase-dependent mechanism. <i>Blood</i> , 2004 , 103, 3516-20	2.2	29
265	Rituximab antiproliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains. <i>Blood</i> , 2004 , 104, 1166-73	2.2	116
264	The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. <i>Blood</i> , 2004 , 104, 3064-71	2.2	500
263	Pharmacokinetic behavior of rituximab: a study of different schedules of administration for heterogeneous clinical settings. 2005 , 27, 785-92		72
262	Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity. <i>Blood</i> , 2005 , 105, 489-95	2.2	144
261	Cholesterol depletion inhibits src family kinase-dependent calcium mobilization and apoptosis induced by rituximab crosslinking. 2005 , 116, 223-32		44
260	In vivo tumouricidal effects of LAD-1 monoclonal antibody on murine RL-male-1 lymphoma mediated by enhanced phagocytosis. 2005 , 141, 54-61		3
259	Monoclonal antibody therapy of cancer. 2005 , 23, 1147-57		916
258	Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. 2005 , 24, 2121-43		240
257	Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis. 2005 , 24, 8114-27		84
256	Concepts in radiotherapy and immunotherapy: anti-CD20 mechanisms of action and targets. 2005 , 32, S19-26		19
255	CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells. 2005 , 304, 88-99		110

254	Rituximab induces different but overlapping sets of genes in human B-lymphoma cell lines. <i>Cancer Immunology, Immunotherapy</i> , 2005 , 54, 273-86	7.4	16
253	Clinical Studies of Immunotherapy With Rituximab (Rituxan [®]) and Radioimmunotherapy With Ibritumomab Tiuxetan (Zevalin [®]) in B-Cell Lymphoid Malignancies. 2005 , 677-709		
252	Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. <i>Blood</i> , 2005 , 106, 3725-32	2.2	1084
251	Generation of rituximab polymer may cause hyper-cross-linking-induced apoptosis in non-Hodgkin's lymphomas. 2005 , 11, 5971-80		65
250	Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. 2005 , 11, 5984-92		145
249	Induction of apoptosis using inhibitors of lysophosphatidic acid acyltransferase-beta and anti-CD20 monoclonal antibodies for treatment of human non-Hodgkin's lymphomas. 2005 , 11, 4857-66		28
248	Induction of lytic Epstein-Barr virus (EBV) infection by synergistic action of rituximab and dexamethasone renders EBV-positive lymphoma cells more susceptible to ganciclovir cytotoxicity in vitro and in vivo. 2005 , 79, 5875-9		35
247	How does B cell depletion therapy work, and how can it be improved?. 2005 , 64 Suppl 4, iv77-80		22
246	A review of tositumomab and I(131) tositumomab radioimmunotherapy for the treatment of follicular lymphoma. 2005 , 5, 577-88		13
245	Enhanced expression of CD20 in human tumor B cells is controlled through ERK-dependent mechanisms. 2005 , 174, 7859-68		33
244	CD20 expression in normal canine B cells and in canine non-Hodgkin lymphoma. 2005 , 42, 468-76		65
243	Anti-CD70 antibodies: a potential treatment for EBV+ CD70-expressing lymphomas. <i>Molecular Cancer Therapeutics</i> , 2005 , 4, 2037-44	6.1	42
242	Treatment strategies in follicular lymphomas: current status and future perspectives. 2005 , 23, 6394-9		72
241	Concurrent administration of granulocyte colony-stimulating factor or granulocyte-monocyte colony-stimulating factor enhances the biological activity of rituximab in a severe combined immunodeficiency mouse lymphoma model. 2005 , 46, 1775-84		35
240	Monoclonal antibodies for immunological disorders: a review of recent patents. 2005 , 15, 1105-1114		
239	The therapeutic potential of anti-CD20 "what do B-cells do?". 2005 , 117, 207-13		98
238	[Rituximab: a original biotherapy in auto-immune disorders]. 2005 , 26, 485-500		9
237	Monoclonal antibodies in the treatment of indolent lymphomas. 2005 , 18, 69-80		10

236	Rituximab Plus Purine Nucleoside Analogs in the Treatment of Indolent Lymphoid Malignancies. 2005 , 4, 279-292		4
235	Review of clinical radioimmunotherapy. 2006 , 6, 445-61		43
234	Pharmacological therapy for Wegener's granulomatosis. 2006 , 66, 1209-28		31
233	The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. 2006 , 177, 362-71		496
232	Targeting B cells in the treatment of childhood-onset systemic lupus erythematosus. 2006 , 148, 571-3		13
231	Cancer therapy with engineered monoclonal antibodies. 2006 , 1, 147-157		11
230	Monoclonal Antibody Therapy of Cancer. 2006 , 487-502		
229	Patterns of expression, membrane localization, and effects of ectopic expression suggest a function for MS4a4B, a CD20 homolog in Th1 T cells. <i>Blood</i> , 2006 , 107, 2400-8	2.2	19
228	Epigenetic processes play a major role in B-cell-specific gene silencing in classical Hodgkin lymphoma. <i>Blood</i> , 2006 , 107, 2493-500	2.2	142
227	Antibody Therapy for Non-Hodgkin's Lymphoma. 2006 , 445-455		
226	Novel agents aiming at specific molecular targets increase chemosensitivity and overcome chemoresistance in hematopoietic malignancies. 2006 , 12, 111-28		18
225	The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma. 2006 , 134, 157-70		27
224	Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines. 2006 , 30, 625-31		68
223	Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies. 2006 , 6, 1161-73		140
222	Fcγ receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity. 2006 , 28, 351-64		52
221	Caspase-independent killing of Burkitt lymphoma cell lines by rituximab. 2006 , 11, 1013-23		39
220	Rituximab added to an intensified salvage chemotherapy program followed by autologous stem cell transplantation improved the outcome in relapsed and refractory aggressive non-Hodgkin lymphoma. 2007 , 86, 107-15		21
219	What signals are generated by anti-CD20 antibody therapy?. <i>Current Hematologic Malignancy Reports</i> , 2006 , 1, 205-13	4.4	8

218	Development of antibody-based therapeutics for oncology indications. 2006 , 67, 699-728	2
217	Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. 2006 , 173, 180-7	327
216	Metabolism-Directed Optimisation of Antithrombotics: The Prodrug Principle. 2006 , 12, 73-91	23
215	Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity. 2006 , 12, 4027-35	188
214	Cutaneous B-cell lymphoma responds to rituximab: a report of five cases and a review of the literature. 2006 , 47, 1902-7	23
213	Apoptosis assays with lymphoma cell lines: problems and pitfalls. 2007 , 96, 928-36	16
212	Fas receptor clustering and involvement of the death receptor pathway in rituximab-mediated apoptosis with concomitant sensitization of lymphoma B cells to fas-induced apoptosis. 2007 , 178, 2287-95	78
211	Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma. 2007 , 7, 257-73	18
210	Evolving therapies for multiple sclerosis. 2007 , 79, 571-88	2
209	Elevation of activated platelet-dependent chemokines in patients with anti-CD20 monoclonal antibody (rituximab)-treated non-Hodgkin's lymphoma. 2007 , 13, 206-12	3
208	Characterization of novel murine anti-CD20 monoclonal antibodies and their comparison to 2B8 and c2B8 (rituximab). 2007 , 31, 29	1
207	Enhanced binding affinity for Fcγ ₃ of fucose-negative antibody is sufficient to induce maximal antibody-dependent cellular cytotoxicity. 2007 , 44, 3122-31	130
206	Mechanisms of killing by anti-CD20 monoclonal antibodies. 2007 , 44, 3823-37	425
205	Apoptosis, Senescence, and Cancer. 2007 ,	6
204	Monoclonal Antibodies. <i>Methods in Molecular Biology</i> , 2007 ,	1.4 1
203	Combination immunotherapy with anti-CD20 and anti-HLA-DR monoclonal antibodies induces synergistic anti-lymphoma effects in human lymphoma cell lines. 2007 , 48, 944-56	12
202	Lym-1-induced apoptosis of non-Hodgkin's lymphomas produces regression of transplanted tumors. 2007 , 22, 342-56	8
201	Targeting B lymphocytes as therapy for ANCA-associated vasculitis. 2007 , 33, 741-54, v	10

200	Update on therapeutic monoclonal antibodies. 2007 , 37, 118-35	8
199	Rheumatoid arthritis and the complement system. 2007 , 39, 517-30	128
198	Therapeutic Antibodies. 2007 , 643-662	
197	Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. 2007 , 56, 1263-72	175
196	Apoptosis and chemo-resistance in colorectal cancer. 2007 , 96, 77-88	38
195	Inhibition of tumor growth in vitro and in vivo by a monoclonal antibody against human chorionic gonadotropin beta. 2007 , 114, 94-102	7
194	Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions. 2007 , 26, 3629-36	165
193	Novel antibodies as anticancer agents. 2007 , 26, 3714-33	71
192	Experiences and problems pre-operative anti-CD20 monoclonal antibody infusion therapy with splenectomy and plasma exchange for ABO-incompatible living-donor liver transplantation. 2007 , 21, 24-31	32
191	Current management of follicular lymphomas. 2007 , 136, 191-202	23
190	Radioimmunotherapy as a therapeutic option for Non-Hodgkin's lymphoma. 2007 , 17, 176-83	21
189	Treatment with rituximab in benign and malignant hematologic disorders in children. 2007 , 150, 338-44, 344.e1	55
188	Monoclonal antibody mechanisms of action in cancer. 2007 , 39, 271-8	86
187	Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases?. 2008 , 34, 124-8	58
186	Treatment of chronic lymphoid leukemias with monoclonal antibodies: current place and perspectives. 2008 , 69, 373-387	1
185	A requirement for calcium in the caspase-independent killing of Burkitt lymphoma cell lines by Rituximab. 2008 , 142, 394-403	20
184	Responses to rituximab vary among follicular lymphoma B cells of different maturation stages. 2008 , 68, 159-68	5
183	The NF-kappaB inhibitors (bortezomib and DHMEQ) sensitise rituximab-resistant AIDS-B-non-Hodgkin lymphoma to apoptosis by various chemotherapeutic drugs. 2008 , 49, 1982-94	25

182	Impact of Polymorphisms on the Clinical Outcomes of Monoclonal Antibody Therapy Against Hematologic Malignancies. 2008 , 203-229		
181	Antibody and immunomodulatory agents in the treatment of indolent non-Hodgkin's lymphoma. 2008 , 45, 85-9		4
180	The mechanism of killing of B-lymphoma cells by 111In-conjugated antibodies. 2008 , 84, 389-99		5
179	In vitro evaluation of radioprotective and radiosensitizing effects of rituximab. 2008 , 49, 674-8		24
178	Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. 2008 , 14, 1561-70		180
177	MS4A12 is a colon-selective store-operated calcium channel promoting malignant cell processes. <i>Cancer Research</i> , 2008 , 68, 3458-66	10.1	49
176	Induction of cytosolic calcium flux by CD20 is dependent upon B Cell antigen receptor signaling. 2008 , 283, 16971-84		108
175	Superior activity of fusion protein scFvRit:sFasL over cotreatment with rituximab and Fas agonists. <i>Cancer Research</i> , 2008 , 68, 597-604	10.1	45
174	Treating multiple sclerosis with monoclonal antibodies. 2008 , 8, 433-55		30
173	Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. 2008 , 26, 1789-96		784
172	Internalisation of uncross-linked rituximab is not essential for the induction of caspase-independent killing in Burkitt lymphoma cell lines. 2008 , 49, 1578-91		2
171	Mouse-human chimeric anti-Tn IgG1 induced anti-tumor activity against Jurkat cells in vitro and in vivo. 2008 , 31, 1739-44		27
170	Pharmacokinetic properties of rituximab. 2008 , 3, 22-30		12
169	Production of therapeutic antibodies with controlled fucosylation. 2009 , 1, 230-6		128
168	Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response. 2009 ,		2
167	Induction of apoptosis by cross-linking antibodies bound to human B-lymphoma cells: expression of Annexin V binding sites on the antibody cap. 2009 , 24, 185-93		8
166	CD20-directed small modular immunopharmaceutical, TRU-015, depletes normal and malignant B cells. 2009 , 15, 2739-46		49
165	Anti-CD20 monoclonal antibody in acute life threatening haemolytic anaemia complicating childhood onset SLE. 2009 , 18, 460-4		15

164	Rituximab-mediated cell signaling and chemo/immuno-sensitization of drug-resistant B-NHL is independent of its Fc functions. 2009 , 15, 6582-94		55
163	In vivo model of follicular lymphoma resistant to rituximab. 2009 , 15, 851-7		32
162	Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood. <i>BMC Cancer</i> , 2009 , 9, 58	4.8	76
161	The involvement of mitochondria and the caspase-9 activation pathway in rituximab-induced apoptosis in FL cells. 2009 , 14, 687-98		32
160	Long-term follow-up analysis after rituximab therapy in children with refractory symptomatic ITP: identification of factors predictive of a sustained response. 2009 , 144, 552-8		41
159	A phase I/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma. 2009 , 23, 912-8		24
158	Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells. 2009 , 33, 465-73		61
157	Effective induction of cell death on adult T-cell leukaemia cells by HLA-DRbeta-specific small antibody fragment isolated from human antibody phage library. 2009 , 145, 799-810		4
156	Immune therapy for cancer. 2009 , 27, 83-117		476
155	Activated T-cell-mediated immunotherapy with a chimeric receptor against CD38 in B-cell non-Hodgkin lymphoma. 2009 , 32, 737-43		37
154	Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab. <i>Blood</i> , 2009 , 113, 3809-12		131
153	Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma. <i>Blood</i> , 2009 , 113, 6161-71	2.2	63
152	Characterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma. <i>Blood</i> , 2009 , 114, 5007-15	2.2	67
151	Mechanisms of Tumor Cell Killing by Therapeutic Antibodies. 111-123		
150	Monoclonal antibodies in the treatment of systemic lupus erythematosus. 2009 , 10, 26-37		29
149	Therapeutic (high) doses of rituximab activate calcium mobilization and inhibit B-cell growth via an unusual mechanism triggered independently of both CD20 and Fcgamma receptors. 2010 , 33, 30-9		5
148	Rituximab is an effective and safe therapeutic alternative in adults with refractory and severe autoimmune hemolytic anemia. 2010 , 89, 1073-80		56
147	Strategies to enhance rituximab anti-tumor activity in the treatment of CD20-positive B-cell neoplasms. 2010 , 46, 192-205		13

146	Highly efficient deletion of FUT8 in CHO cell lines using zinc-finger nucleases yields cells that produce completely nonfucosylated antibodies. 2010 , 106, 774-83	129
145	Nonfucosylated anti-CD20 antibody potentially induces apoptosis in lymphoma cells through enhanced interaction with FcγRIIIb on neutrophils. 2010 , 34, 666-71	13
144	High immunohistochemical expression of p-AKT predicts inferior survival in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. 2010 , 149, 560-8	62
143	Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma. 2010 , 151, 37-46	32
142	Rituximab for the treatment of patients with chronic lymphocytic leukemia. 2010 , 2, 71-81	4
141	Transplant Pharmacology. 2010 , 352-356	
140	Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia. 2010 , 10, 1529-43	15
139	Rituximab for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. 2010 , 70, 261-72	38
138	Infusion reactions: diagnosis, assessment, and management. 2010 , 14, E10-21	136
137	Ofatumumab, a human anti-CD20 monoclonal antibody. 2010 , 10, 439-49	15
136	Experimentally induced liver metastases from colorectal cancer can be prevented by mononuclear phagocyte-mediated monoclonal antibody therapy. 2010 , 53, 677-85	38
135	CD20-targeted therapy: the next generation of antibodies. 2010 , 47, 199-210	77
134	Rituximab: mechanism of action. 2010 , 47, 115-23	519
133	Cancer immunotherapy. 2011 , 26, 1-64	102
132	Rituximab resistance. 2011 , 24, 203-16	147
131	Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study. 2011 , 12, 361-8	135
130	Molecular mechanisms of the antitumor effects of anti-CD20 antibodies. 2011 , 16, 277-306	34
129	Radioimmunotherapy of solid tumors: searching for the right target. 2011 , 8, 26-44	43

128	Rituximab regulates signaling pathways and alters gene expression associated with cell death and survival in diffuse large B-cell lymphoma. 2011 , 25, 1183-90		12
127	Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin $\alpha 4 \beta 1$ (VLA-4) with natalizumab can overcome this resistance. 2011 , 155, 53-64		80
126	The impact of Fc γ receptor polymorphisms in elderly patients with diffuse large B-cell lymphoma treated with CHOP with or without rituximab. <i>Blood</i> , 2011 , 118, 4657-62	2.2	51
125	Direct effect of rituximab in B-cell-derived lymphoid neoplasias: mechanism, regulation, and perspectives. 2011 , 9, 1435-42		35
124	Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101. <i>Molecular Cancer Therapeutics</i> , 2011 , 10, 178-85	6.1	106
123	Interindividual variability of response to rituximab: from biological origins to individualized therapies. 2011 , 17, 19-30		69
122	Fundamental technologies for antibody engineering. 2012 , 57-595		
121	Sources of antibody variable chains. 2012 , 77-595		
120	Development issues: antibody stability, developability, immunogenicity, and comparability. 2012 , 377-595		5
119	The Role of Rituximab in the Therapy of Mixed Cryoglobulinemia. 2012 , 297-305		
118	Therapeutic antibody classes. 2012 , 197-595		1
117	Monoclonal antibody targets and mechanisms of action. 2012 , 163-595		1
116	Cell line development. 2012 , 421-595		1
115	Anti-tumor monoclonal antibodies in conjunction with β glucans: a novel anti-cancer immunotherapy. 2012 , 19, 4298-305		17
114	Introduction to biologics and monoclonal antibodies. 2012 , 1-595		2
113	2nd PEGS Annual Symposium on Antibodies for Cancer Therapy: April 30-May 1, 2012, Boston, USA. 2012 , 4, 562-70		5
112	Value proposition for therapeutic monoclonal antibodies and Fc fusion proteins. 2012 , 15-595		
111	Antibody Fc engineering for optimal antibody performance. 2012 , 225-595		

110	Antibody structure-function relationships. 2012 , 37-595	
109	Issues facing therapeutic monoclonal antibodies for the future. 2012 , 439-595	1
108	Antibody-drug conjugates. 2012 , 345-595	2
107	Denileukin diftitox in combination with rituximab for previously untreated follicular B-cell non-Hodgkin's lymphoma. 2012 , 26, 1046-52	19
106	Class-specific effector functions of therapeutic antibodies. <i>Methods in Molecular Biology</i> , 2012 , 901, 295-347	2
105	Treatment of antineutrophil cytoplasmic antibody-associated vasculitis with rituximab. 2012 , 24, 15-23	33
104	Antibody interactions with the immune system. 2012 , 131-595	
103	IgG glycans and glyco-engineering. 2012 , 251-595	
102	Antibody fragments as therapeutics. 2012 , 265-595	1
101	Multiple antibody and multi-specificity approaches. 2012 , 299-595	
100	FcFPs and similar constructs using Fc. 2012 , 329-595	
99	Interactions of human IgGs with non-human systems. 2012 , 405-595	
98	Variable chain engineering humanization and optimization approaches. 2012 , 111-595	
97	Novel and emerging drugs for acute lymphoblastic leukemia. 2012 , 12, 505-21	2
96	Anti-CD20 IgA can protect mice against lymphoma development: evaluation of the direct impact of IgA and cytotoxic effector recruitment on CD20 target cells. 2012 , 97, 1686-94	27
95	Therapeutic antibodies against cancer. 2012 , 26, 447-81, vii	59
94	Clinical use of biologics in vasculitis syndromes. 2012 , 6, 371-8	3
93	Immunotherapy of Cancer. 2012 , 391-414	12

92	The interactions of therapeutic antibodies with Fc receptors. 2012 , 143, 20-7		19
91	Homozygous A polymorphism of the complement C1qA276 correlates with prolonged overall survival in patients with diffuse large B cell lymphoma treated with R-CHOP. 2012 , 5, 51		19
90	Expression of CD20 reveals a new store-operated calcium entry modulator in skeletal muscle. 2012 , 44, 2095-105		8
89	Generation of a potent recombinant homophilic chimeric anti-CD20 antibody. 2012 , 31, 395-402		1
88	Efficacy and safety of rituximab therapy for systemic lupus erythematosus: a systematic review and meta-analysis. 2012 , 13, 731-44		23
87	Innate Immune Regulation and Cancer Immunotherapy. 2012 ,		3
86	Immunotherapy for B-cell lymphoma: current status and prospective advances. 2012 , 3, 3		14
85	Mast cells and company. 2012 , 3, 16		49
84	Identification of patients with indolent B cell lymphoma sensitive to rituximab monotherapy. 2012 , 91, 715-721		18
83	Resistance to Immunotherapeutic Antibodies in Cancer. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2013 ,	0.3	1
82	Real time analysis of binding between Rituximab (anti-CD20 antibody) and B lymphoma cells. 2013 , 85, 8543-51		19
81	Rituximab-induced acute severe thrombocytopenia: a case series in patients with mantle cell lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013 , 13, 602-5	2	9
80	Rituximab biosimilars. 2013 , 13, 1049-62		30
79	Non-Hodgkin's B-cell lymphoma: advances in molecular strategies targeting drug resistance. 2013 , 238, 971-90		38
78	Hypoxia inducible factor-1 α induces chemoresistance phenotype in non-Hodgkin lymphoma cell line via up-regulation of Bcl-xL. 2013 , 54, 1048-55		24
77	TGF- β induced apoptosis of B-cell lymphoma Ramos cells through reduction of MS4A1/CD20. 2013 , 32, 2096-106		20
76	Biologic response modifiers for granulomatosis with polyangiitis (Wegener's): from promise to reality. 2013 , 8, 383-397		
75	No Mechanism is an Island. 2014 , 257-267		

74	Rituximab: modes of action, remaining dispute and future perspective. 2014 , 10, 2481-92		31
73	Fc Receptors in Immune Responses. 2014 ,		1
72	Enhancement of Rituximab-induced cell death by the physical association of CD20 with CD40 molecules on the cell surface. 2014 , 26, 451-65		11
71	Time now to TORC the TORC? New developments in mTOR pathway inhibition in lymphoid malignancies. 2014 , 166, 336-51		36
70	Experience with rituximab in the treatment of antineutrophil cytoplasmic antibody associated vasculitis. 2014 , 6, 58-74		8
69	Obinutuzumab (Gazyva [®]), a Novel Glycoengineered Type II CD20 Antibody for the Treatment of Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma. 2014 , 1695-1732		2
68	Super-Resolution Imaging and Quantitative Analysis of Membrane Protein/Lipid Raft Clustering Mediated by Cell-Surface Self-Assembly of Hybrid Nanoconjugates. 2015 , 16, 1725-9		24
67	Building better monoclonal antibody-based therapeutics. 2015 , 15, 361-70		411
66	Multimodality imaging of coiled-coil mediated self-assembly in a "drug-free" therapeutic system. 2015 , 4, 1054-65		26
65	Immune reconstitution and infectious complications after rituximab treatment in children and adolescents: what do we know and what can we learn from adults?. <i>Cancers</i> , 2015 , 7, 305-28	6.6	30
64	The preclinical discovery of rituximab for the treatment of non-Hodgkin's lymphoma. 2015 , 10, 791-808		7
63	Localized Store-Operated Calcium Influx Represses CD95-Dependent Apoptotic Effects of Rituximab in Non-Hodgkin B Lymphomas. 2015 , 195, 2207-15		18
62	Mechanisms of action of therapeutic antibodies for cancer. 2015 , 67, 28-45		98
61	Human lymphocytic B-leukemia cell line treatment with the bacterial toxin listeriolysin O and rituximab (anti-CD20 antibody): Effects of similar localization of their receptors. <i>International Journal of Immunopathology and Pharmacology</i> , 2015 , 28, 329-40	3	1
60	The status of radioimmunotherapy in CD20+ non-Hodgkin's lymphoma. <i>Targeted Oncology</i> , 2015 , 10, 15-26	5	12
59	Biodrug Delivery Systems. 2016 ,		4
58	Response of Chronic, Relapsing Wegener's Granulomatosis with Severe Pulmonary Involvement to Anti-CD20 Monoclonal Antibody (Rituximab). <i>Journal of Neurology and Neuroscience</i> , 2016 , 07,	0	0
57	NMO-Spektrum-Erkrankungen. <i>InFo Neurologie & Psychiatrie</i> , 2016 , 18, 39-51	0	

56	Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas. <i>Cancer Research</i> , 2017 , 77, 3885-3893	10.1	18
55	Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development. <i>Advances in Therapy</i> , 2017 , 34, 2210-2231	4.1	39
54	Rituximab response in follicular lymphoma is associated with the rs20575 polymorphism in TRAILR1 extrinsic apoptosis trigger. <i>Pharmacogenetics and Genomics</i> , 2017 , 27, 70-77	1.9	4
53	Targeting Oncoproteins for Molecular Cancer Therapy. 2017 , 727-756		
52	Tumour cell surface antigen targeted therapies in B-cell lymphomas: Beyond rituximab. <i>Blood Reviews</i> , 2017 , 31, 23-35	11.1	13
51	A Phase II Trial of Rituximab Combined With Pegfilgrastim in Patients With Indolent B-cell Non-Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018 , 18, e51-e60	2	5
50	Novel immunotherapy approaches to follicular lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2018 , 2018, 194-199	3.1	5
49	Mechanisms of Resistance to Monoclonal Antibodies (mAbs) in Lymphoid Malignancies. <i>Current Hematologic Malignancy Reports</i> , 2019 , 14, 426-438	4.4	8
48	Current targeted therapies in lymphomas. <i>American Journal of Health-System Pharmacy</i> , 2019 , 76, 1825-1834	18.4	13
47	Characterization of zolbetuximab in pancreatic cancer models. <i>Oncolmmunology</i> , 2019 , 8, e1523096	7.2	12
46	Follicular Lymphoma. 2020 ,		
45	Intratumoral injection reduces toxicity and antibody-mediated neutralization of immunocytokine in a mouse melanoma model. 2020 , 8,		7
44	Co-delivery of rituximab targeted curcumin and imatinib nanostructured lipid carriers in non-Hodgkin lymphoma cells. <i>Journal of Liposome Research</i> , 2021 , 31, 64-78	6.1	10
43	Efficacy of Targeted Immunotherapy as Induction or Salvage Therapy in Acute Lymphoblastic Leukemia: A Systematic Review and Meta-Analysis. <i>Technology in Cancer Research and Treatment</i> , 2021 , 20, 15330338211037434	2.7	
42	Harnessing Tumor Necrosis Factor Alpha to Achieve Effective Cancer Immunotherapy. <i>Cancers</i> , 2021 , 13,	6.6	14
41	Anti-GD2 antibody disrupts GD2:Siglec-7 interactions and synergizes with CD47 blockade to mediate tumor eradication.		
40	The clinical efficacy of Rituximab administration in autoimmunity disorders, primary immunodeficiency diseases and malignancies. <i>International Immunopharmacology</i> , 2021 , 95, 107565	5.8	2
39	The 'cytokine storm': molecular mechanisms and therapeutic prospects. <i>Trends in Immunology</i> , 2021 , 42, 681-705	14.4	36

38	Quantification of surface antigens and quantitative flow cytometry. <i>Methods in Molecular Biology</i> , 2007 , 378, 65-9	1.4	1
37	Monoclonal antibody therapy. 2009 , 303-406		3
36	Monoclonal antibody therapy. 2003 , 329-390		2
35	Rituximab. <i>Cancer Chemotherapy and Biological Response Modifiers</i> , 2003 , 235-258		2
34	Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects. <i>Blood</i> , 2002 , 100, 1765-1773	2.2	94
33	The Discovery of Rituxan. 2006 , 565-584		1
32	Antibodies against CD20 or B-cell receptor induce similar transcription patterns in human lymphoma cell lines. <i>PLoS ONE</i> , 2011 , 6, e16596	3.7	18
31	Use of rituximab in systemic lupus erythematosus in children: a review. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2019 , 57, 578-583	0.9	3
30	Next generation of antibody therapy for cancer. <i>Chinese Journal of Cancer</i> , 2011 , 30, 293-302		8
29	MS4A15 drives ferroptosis resistance through calcium-restricted lipid remodeling. <i>Cell Death and Differentiation</i> , 2021 ,	12.7	3
28	Signal transduction therapy. 2002 , 53-66		
27	Immunotoxin Therapy of Chronic Lymphocytic Leukemia. 2004 , 299-314		
26	Biological Therapy of Non-Hodgkin's Lymphomas. 2006 , 249-277		
25	Chemo-Immunosensitization of Resistant B-NHL as a Result of Rituximab (anti-CD20 mAb)-Mediated Inhibition of Cell Survival Signaling Pathways. 2008 , 29-39		
24	B cell targets in rheumatoid arthritis. 2009 , 1-26		
23	Biologic Therapies For Non-hodgkin Lymphoma And Hodgkin Disease. 2009 ,		
22	Monoclonal Antibodies in Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies. 2010 , 733-746		
21	References. 2012 , 459-595		1

20	Understanding the Mechanisms of Resistance to Rituximab: Paving the Road for the Development of Therapeutic Strategies to Overcome Rituximab-Resistance. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2013 , 73-92	0.3	
19	Tumor Resistance to Antibody-Mediated Immunotherapy and Reversal of Resistance: Rituximab as Prototype. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2013 , 93-124	0.3	
18	Immediate Reactions To Monoclonal Antibodies In Clinical Hematology. <i>International Journal of Medicine and Surgery</i> , 2016 , 3, 32-39	0	
17	Resistance to Monoclonal Antibody Therapeutics in Lymphoma. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2019 , 27-55	0.3	
16	Targeting the Tumor Microenvironment. 2020 , 219-231		
15	Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma. <i>Cancer Treatment and Research</i> , 2006 , 131, 221-50	3.5	1
14	Genetic Immunotherapy Approaches. 2005 , 129-141		2
13	Monoclonal Antibodies in Lymphomas. 2007 , 511-536		
12	Antibody Therapy of Cancer. 2008 , 371-412		
11	Spatiotemporally light controlled drug-free macromolecules via upconversion-nanoparticle for precise tumor therapy. <i>Nano Today</i> , 2022 , 42, 101360	17.9	1
10	Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication.. <i>Nature Medicine</i> , 2022 ,	50.5	6
9	Follicular lymphomas. 338-366		
8	Monoclonal antibodies for the treatment of acute lymphocytic leukemia: A literature review. <i>Human Antibodies</i> , 2022 , 1-14	1.3	
7	Exploring complement-dependent cytotoxicity by rituximab isotypes in 2D and 3D-cultured B-cell lymphoma. <i>BMC Cancer</i> , 2022 , 22,	4.8	0
6	Rituximab (Chimeric Anti-CD20 Monoclonal Antibody) Inhibits the Constitutive Nuclear Factor- κ B Signaling Pathway in Non-Hodgkin's Lymphoma B-Cell Lines: Role in Sensitization to Chemotherapeutic Drug-induced Apoptosis. 2005 , 65, 264-276		38
5	Enhanced efficacy of therapy with antisense BCL-2 oligonucleotides plus anti-CD20 monoclonal antibody in scid mouse/human lymphoma xenografts. <i>Molecular Cancer Therapeutics</i> , 2004 , 3, 1693-1699	6.1	2
4	Development of anti-rituximab antibodies in rituximab-treated patients: Related parameters & consequences. 2022 , 155, 335		0
3	Making Rituximab Directly Cytotoxic for Substantial Improvement in Therapeutic Efficacy. 82-90		0

- 2 Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOMentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trial. **2022**, 86, 104321 ○
- 1 Endemic Burkitt lymphoma avatar mouse models for exploring inter-patient tumor variation and testing targeted therapies. **2023**, 6, e202101355 ○